Virus-like particle display of HER2 induces potent anti-cancer responses
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Virus-like particle display of HER2 induces potent anti-cancer responses. / Palladini, Arianna; Thrane, Susan; Janitzek, Christoph M; Pihl, Jessica; Clemmensen, Stine B; de Jongh, Willem Adriaan; Clausen, Thomas M; Nicoletti, Giordano; Landuzzi, Lorena; Penichet, Manuel L; Balboni, Tania; Ianzano, Marianna L; Giusti, Veronica; Theander, Thor G; Nielsen, Morten A; Salanti, Ali; Lollini, Pier-Luigi; Nanni, Patrizia; Sander, Adam F.
I: OncoImmunology, Bind 7, Nr. 3, e1408749, 2018.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Virus-like particle display of HER2 induces potent anti-cancer responses
AU - Palladini, Arianna
AU - Thrane, Susan
AU - Janitzek, Christoph M
AU - Pihl, Jessica
AU - Clemmensen, Stine B
AU - de Jongh, Willem Adriaan
AU - Clausen, Thomas M
AU - Nicoletti, Giordano
AU - Landuzzi, Lorena
AU - Penichet, Manuel L
AU - Balboni, Tania
AU - Ianzano, Marianna L
AU - Giusti, Veronica
AU - Theander, Thor G
AU - Nielsen, Morten A
AU - Salanti, Ali
AU - Lollini, Pier-Luigi
AU - Nanni, Patrizia
AU - Sander, Adam F
PY - 2018
Y1 - 2018
N2 - Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination may represent a safer, more effective and cheaper alternative, although the induction of strong and durable autoantibody responses is hampered by immune-tolerogenic mechanisms. Using a novel virus-like particle (VLP) based vaccine platform we show that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses. Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice. The HER2-VLP vaccine shows promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer. The VLP platform may represent an effective tool for development of vaccines against other non-communicable diseases.
AB - Overexpression of human epidermal growth factor receptor-2 (HER2) occurs in 20-30% of invasive breast cancers. Monoclonal antibody therapy is effective in treating HER2-driven mammary carcinomas, but its utility is limited by high costs, side effects and development of resistance. Active vaccination may represent a safer, more effective and cheaper alternative, although the induction of strong and durable autoantibody responses is hampered by immune-tolerogenic mechanisms. Using a novel virus-like particle (VLP) based vaccine platform we show that directional, high-density display of human HER2 on the surface of VLPs, allows induction of therapeutically potent anti-HER2 autoantibody responses. Prophylactic vaccination reduced spontaneous development of mammary carcinomas by 50%-100% in human HER2 transgenic mice and inhibited the growth of HER2-positive tumors implanted in wild-type mice. The HER2-VLP vaccine shows promise as a new cost-effective modality for prevention and treatment of HER2-positive cancer. The VLP platform may represent an effective tool for development of vaccines against other non-communicable diseases.
U2 - 10.1080/2162402X.2017.1408749
DO - 10.1080/2162402X.2017.1408749
M3 - Journal article
C2 - 29399414
VL - 7
JO - OncoImmunology
JF - OncoImmunology
SN - 2162-4011
IS - 3
M1 - e1408749
ER -
ID: 189601802